Effectiveness and safety of dupilumab in moderate-to-severe atopic dermatitis patients with chronic renal insufficiency: a real-world retrospective study in China

Cong Peng; Qiaozhi Cao; Feng Xiong; Hui Xu; Jie Li

doi:10.1002/mco2.707

MedComm ›› 2024, Vol. 5 ›› Issue (10) : e707 DOI: 10.1002/mco2.707

LETTER

Effectiveness and safety of dupilumab in moderate-to-severe atopic dermatitis patients with chronic renal insufficiency: a real-world retrospective study in China

Author information +

History +

PDF

Cite this article

Download citation ▾

Cong Peng, Qiaozhi Cao, Feng Xiong, Hui Xu, Jie Li. Effectiveness and safety of dupilumab in moderate-to-severe atopic dermatitis patients with chronic renal insufficiency: a real-world retrospective study in China. MedComm, 2024, 5(10): e707 DOI:10.1002/mco2.707

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]

Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017; 389(10086): 2287-2303.

[2]	Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019; 143(1): 155-172.

[3]	Yi XQ, Cao QZ, Peng C, Jia QQ, Li J. Baseline eosinophil level may be a predictive indicator for the effectiveness of dupilumab in patients with prurigo nodularis: a single-center, real-world prospective study. J Am Acad Dermatol. 2024; 90(5): 1076-1078.

[4]	Ko MJ, Peng YS, Chen HY, et al. Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis. J Am Acad Dermatol. 2014; 71(6): 1151-1159. e1.

[5]	Silverberg JI, Brieva J. A successful case of dupilumab treatment for severe uremic pruritus. JAAD Case Rep. 2019; 5(4): 339-341.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.